Optimal Target Low-density Lipoprotein Level for Reducing the Risk of Atherosclerotic Cardiovascular Diseases: A Systematic Review and Meta-analysis
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: As per guidelines for treating dyslipidemia, the recommended low-density lipoprotein cholesterol (LDL-C) level in extremely high-risk patients, including those with coronary artery diseases is <55 mg/dL. Although this recommendation has been adopted in the guidelines for dyslipidemia in various countries, there is limited evidence of its efficacy in reducing cardiovascular diseases (CVDs), especially among East Asian patients. This study aimed to investigate whether an LDL-C value below 55 mg/dL is associated with decreased risk of CVDs. Methods: Seven clinical trials including 50,970 patients that compared intensive lipidlowering therapy with less therapy or placebo in patients who had >6 months of follow-up, those with a sample size of ≥150 were selected as the final literature for analysis. Risk ratios (RR) using random effects were represented with 95% confidence intervals (CI) for the reliability of the results. Results: An LDL-C level of <55 mg/dL was related to significantly reduced events of major CVDs (RR: 0.88; 95% CI: 0.80-0.98) and myocardial infarction (RR: 0.81; 95% CI: 0.73-0.90) and a reduced risk of ischemic stroke (RR 0.79; 95% CI 0.69-0.89, mean follow-up=2 years). However, an LDL-C level below 55 mg/dL did not reduce the incidence of CVD in intensive therapy in East Asian patients. Conclusions: A goal LDL-C value below 55 mg/dL was identified to be related to a decreased risk of developing CVD. However, the relation to LDL-C below 55 mg/dL with a decreased risk of CVD was not observed in East Asian patients.
Abstract
Background: As per guidelines for treating dyslipidemia, the recommended low-density lipoprotein cholesterol (LDL-C) level in extremely high-risk patients, including those with coronary artery diseases is <55 mg/dL. Although this recommendation has been adopted in the guidelines for dyslipidemia in various countries, there is limited evidence of its efficacy in reducing cardiovascular diseases (CVDs), especially among East Asian patients. This study aimed to investigate whether an LDL-C value below 55 mg/dL is associated with decreased risk of CVDs. Methods: Seven clinical trials including 50,970 patients that compared intensive lipidlowering therapy with less therapy or placebo in patients who had >6 months of follow-up, those with a sample size of ≥150 were selected as the final literature for analysis. Risk ratios (RR) using random effects were represented with 95% confidence intervals (CI) for the reliability of the results. Results: An LDL-C level of <55 mg/dL was related to significantly reduced events of major CVDs (RR: 0.88; 95% CI: 0.80-0.98) and myocardial infarction (RR: 0.81; 95% CI: 0.73-0.90) and a reduced risk of ischemic stroke (RR 0.79; 95% CI 0.69-0.89, mean follow-up=2 years). However, an LDL-C level below 55 mg/dL did not reduce the incidence of CVD in intensive therapy in East Asian patients. Conclusions: A goal LDL-C value below 55 mg/dL was identified to be related to a decreased risk of developing CVD. However, the relation to LDL-C below 55 mg/dL with a decreased risk of CVD was not observed in East Asian patients.
참고문헌 (27)
- Mach F, "2019 ESC", EAS guidelines for the management of dyslipidaemias : lipid modification to reduce cardiovascular risk, 2019, pp.290, 140~205
- Handelsman Y, "Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the management of dyslipidemia and prevention of cardiovascular disease algorithm-2020 executive summary", Endocrr Pract, 26(10), pp.1196~1224 (2020)
- "The Korean Society of Lipid and Atherosclerosis (KSoLA)Committee of Clinical Practice Guideline. Korean guidelines for the management of dyslipidemia"[URL]
- Cannon CP, "Ezetimibe added to statin therapy after acute coronary syndromes", N Engl J Med, 372(25), pp.2387~2397 (2015)
- Sabatine MS, "Evolocumab and clinical outcomes in patients with cardiovascular disease", N Engl J Med, 376(18), pp.1713~1722 (2017)
- Schwartz GG, "Alirocumab and cardiovascular outcomes after acute coronary syndrome", N Engl J Med, 379, pp.2097~2107 (2018)
- Keech AC, "Efficacy and safety of longterm evolocumab use among Asian subjects-a subgroup analysis of the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk(FOURIER)trial", Circ J, 85(11), pp.2063~2070 (2021)
- Martin SS, "LDL cholesterol : the lower the better", Med Clin North Am, 96(1), pp.13~26 (2012)
- Navarese EP, "Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering : a systematic review and metaanalysis", JAMA, 319(15), pp.1566~1579 (2018)
- Khan SU, "Efficacy and safety for the achievement of guideline-recommended lower low-density lipoprotein cholesterol levels : a systematic review and metaanalysis", Eur J Prev Cardiol, 28(18), pp.2001~2009 (2021)
- Riaz H, "Effects of high-density lipoprotein targeting treatments on cardiovascular outcomes : A systematic review and meta-analysis", Eur J Prev Cardiol, 26(5), pp.533~543 (2019)
- Higgins JPT, "Measuring inconsistency in meta-analyses", BMJ, 327(7414), pp.557~560 (2003)
- 남재현, "만성신장병환자에서 apixaban과 warfarin의 안전성 비교: 체계적 문헌고찰 및 메타분석", 한국임상약학회지, 31(2), pp.87~95 (2021), 한국임상약학회[DOI]
- Penson PE, "LDL-C : lower is better for longereven at low risk", BMC Med, 18(1), pp.1~6 (2020)
- Ference BA, "Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel", Eur Heart J, 38(32), pp.2459~2472 (2017)
- Cannon CP, "Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy", J Am Coll Cardiol, 48(3), pp.438~445 (2006)
- Nissen SE, "Effect of very high-intensity statin therapy on regression of coronary atherosclerosis : the ASTEROID trial", JAMA, 295(13), pp.1556~1565 (2006)
- Ahn JH, "Optimal low-density lipoprotein cholesterol target level in Korean acute myocardial infarction patients (<70 mg", dL vs. <55 mg, Int J Cardiol, pp.2022, 351[DOI]
- Jellinger PS, "American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease", Endocr Pract, 23(Suppl 2), pp.1~87 (2017)
- Khan SU, "Association of baseline LDL-C with total and cardiovascular mortality in patients using proprotein convertase subtilisin-kexin type 9 inhibitors : a systematic review and meta-analysis", J Clin Lipidol, 13(4), pp.538~549 (2019)
- Sakamo to T, "“Just make it lower” is an alternative strategy of lipid-lowering therapy with statins in Japanese patients:LDL-cholesterol: the lower, the better; is it true for Asians? (Con)", Circ J, 74(8), pp.1731~1741 (2010)
- T eramoto T, "Efficacy and safety of alirocumab 150 mg every 4 weeks in hypercholesterolemic patients on non-statin lipid-lowering therapy or lowest strength dose of statin : ODYSSEY NIPPON", J Cardiol, 73(3), pp.218~227 (2019)
- Koh KK, "A randomized trial evaluating the efficacy and safety of alirocumab in south korea and taiwan(ODYSSEY-KT)", J Clin Lipidol, 12(1), pp.162~172 (2018)
- Liu Z, "Therapeutic effects of atorvastatin and ezetimibe compared with double-dose atorvastatin in very elderly patients with acute coronary syndrome", Oncotarget, 8(25), pp.41582~41589 (2017)
- T eramoto, "Efficacy and safety of alirocumab in Japanese patients with heterozygous familial hypercholesterolemia or at high cardiovascular risk with hypercholesterolemia not adequately controlled with statins – ODYSSEY JAPAN randomized controlled trial", Cir J, 80(9), pp.1980~1987 (2016)
- Sabatine MS, "Efficacy and safety of evolocumab in reducing lipids and cardiovascular events", N Engl J Med, 372, pp.1500~1509 (2015)